Genetic associations of LXN polymorphisms with toxicities of platinum-based concurrent chemoradiotherapy of nasopharyngeal carcinoma
Supportive Care in Cancer · 2026
DOI: 10.1007/s00520-026-10378-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, 2026. Verfasst von Youhong Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xiamen Children's Hospital (Children's Hospital of Fudan University at Xiamen), Xiamen, 361000, P. R. China. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms, Chemoradiotherapy, Stomatitis. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: Oral mucositis (OM) is a common and debilitating adverse effect associated with chemoradiotherapy in nasopharyngeal carcinoma. This study aimed to investigate the association between Latexin (LXN) polymorphism and acute toxicity of oral mucositis. METHODS: A total of 238 nasopharyngeal carcinoma (NPC) patients were enrolled. LXN genotypes were analyzed by the Sequenom MassARRAY system. Multivariate logistic regression was performed to assess the association of LXN polymorphisms and chemoradiotherapy-induced toxicities. Multifactor and generalized multifactor dimensionality reduction methods were applied to calculate the SNP-SNP interaction. RESULTS: Our study showed that the frequency of the AG genotype of rs1492908 was significantly lower in the grade 3-4 oral mucositis group compared to the grade 0-2 group (14.1% vs. 27.1%, respectively). Patients carrying the LXN rs1492908 AG genotype exhibited a decreased risk of severe oral mucositis (OR = 0.452, 95% CI = 0.213-0.959, P = 0.039). Stratification analysis further revealed that the rs1492908 AG genotype conferred protective effects against oral mucositis in specific patient populations, including those aged ≥ 47 years (OR = 0.340, P = 0.041), body mass index (BMI) ≥ 24 (OR = 0.286, P = 0.035), WHO type Ⅲ histology (OR = 0.212, P = 0.007), and receiving a higher radiotherapy dose (planning gross tumor volume of nasopharynx (pGTVnx) ≥ 71 Gy) (OR = 0.158, P = 0.016). Additionally, SNP-SNP interaction analysis identified that the combination of rs1492908, rs9841, rs8455, rs2639655, and rs56321207 was the best multi-locus model for oral mucositis. CONCLUSION: This study is the first to establish a link between NPC chemoradiotherapy-induced oral mucositis risk and LXN polymorphisms in the Chinese Han population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Xiamen Children's Hospital (Children's Hospital of Fudan University at Xiamen), Xiamen, 361000, P. R. China.
- Fujian Key Laboratory of Neonatal Diseases, Xiamen Key Laboratory of Neonatal Diseases, Xiamen Children's Hospital (Children's Hospital of Fudan University at Xiamen), Xiamen, 361000, P. R. China.
- Department of Pharmacy, Hunan Chest Hospital, Changsha, Hunan, P. R. China.
- College of Pharmacy, Changsha Medical University, Changsha, Hunan, P. R. China.
- Department of Laboratory Medicine, The Fourth Hospital of Baotou, Baotou, Inner Mongolia, P. R. China.
- Department of Radiology, Sinopharm Northern Hospital, Baotou, Inner Mongolia, P. R. China. bfyyfskf@163.com.
Zitieren
APA
Wang, Y., Ma, S., Bao, J., Zhang, Z., Song, J., Tai, Y., Gao, Y., Feng, W., & An, L. (2026). Genetic associations of LXN polymorphisms with toxicities of platinum-based concurrent chemoradiotherapy of nasopharyngeal carcinoma. Supportive Care in Cancer. https://doi.org/10.1007/s00520-026-10378-7
Vancouver
Wang Y, Ma S, Bao J, Zhang Z, Song J, Tai Y, et al. Genetic associations of LXN polymorphisms with toxicities of platinum-based concurrent chemoradiotherapy of nasopharyngeal carcinoma. Supportive Care in Cancer. 2026. doi:10.1007/s00520-026-10378-7
BibTeX
@article{Wang2026,
author = {Wang, Youhong and Ma, Siqing and Bao, Jiancheng and Zhang, Zehong and Song, Jiachun and Tai, Yu and Gao, Yingting and Feng, Wei and An, Liang},
title = {Genetic associations of LXN polymorphisms with toxicities of platinum-based concurrent chemoradiotherapy of nasopharyngeal carcinoma},
journal = {Supportive Care in Cancer},
year = {2026},
doi = {10.1007/s00520-026-10378-7}
}
EUVIMED